Soligenix Inc Stock Price, News & Analysis

Soligenix, a late-stage biopharmaceutical company, is urging eligible stockholders to vote 'FOR' a Reverse Stock Split. The company aims to maintain its Nasdaq listing, which is critical for advancing its HyBryte™ Phase 3 trial and other clinical programs, as well as securing institutional support and potential non-dilutive government funding. Eligible stockholders as of April 10, 2024, can vote by contacting Alliance Advisors at 1-833-782-7145. Soligenix emphasizes that even those who have sold their shares after this date are still eligible to vote.

Soligenix announced that Professor Axel Lehrer from the University of Hawaiʽi will present data on their thermostable vaccine technology at the Vaccine Technology IX Conference in Los Cabos, Mexico, from May 19-24, 2024. The technology includes filovirus vaccine candidates SuVax™ and MarVax™. The presentation will cover the optimization of vaccine formulation focused on safety and thermostability. Soligenix's vaccines, developed under their Public Health Solutions segment, use GRAS excipients and lyophilization for stability, protecting against Sudan ebolavirus and Marburg marburgvirus in non-human primate studies. The company has received Orphan Drug Designation for these vaccines.

Soligenix (Nasdaq: SNGX), a biopharmaceutical company focused on rare diseases, urges stockholders to vote in the Annual Meeting on May 23, 2024. This meeting, to be held virtually at 9:00 AM ET, is important for advancing the company's pipeline, including a Phase 3 study of HyBryte™ for cutaneous T-cell lymphoma (CTCL). Voting is open to stockholders of record as of April 10, 2024, even if shares have been sold since. Voting can be done online, by phone, or by mail until 11:59 PM ET on May 22, 2024.

Soligenix announced positive results from its HyBryte™ compatibility study for treating cutaneous T-cell lymphoma (CTCL), published in JEADV Clinical Practice. The study, HPN-CTCL-02, enrolled 9 patients, revealing a 22% treatment response rate after 8 weeks of HyBryte™ therapy. The results align with the Phase 3 FLASH trial, showing an average improvement of 36.4% in cumulative mCAILS scores. Key metrics included low systemic hypericin levels and no adverse effects on cardiac rhythm, confirming HyBryte™'s safety. The study points to the potential real-world use of HyBryte™ and precedes a confirmatory Phase 3 FLASH2 study.

Soligenix, a biopharmaceutical company, announced recent accomplishments and first quarter 2024 financial results. They completed a public offering with gross proceeds of $4.75 million, received orphan drug designations, and initiated various clinical trials. The company's revenue decreased to $0.1 million, net loss increased to $1.9 million, research and development expenses grew due to upcoming trials, and general and administrative expenses decreased. Cash position was $7.1 million as of March 31, 2024.

Soligenix, Inc. (Nasdaq: SNGX) announced its participation in upcoming conferences like the Aegis Virtual Conference, BioNJ's 14th Annual BioPartnering Conference, and A.G.P./Alliance Global Partners Healthcare Company Showcase. These events provide opportunities for presentations, networking, and one-on-one meetings with key members of Soligenix management. The Company aims to deliver a corporate presentation to investors, institutional funds, and money managers, showcasing its late-stage biopharmaceutical products for rare diseases.